

# *An updated analysis of opioids increasing the risk of fractures*

2

3 Short title: Opioids and fractures

4

5 Qiaoning Yue <sup>1</sup>, Yue Ma <sup>2</sup>, Yirong Teng <sup>3</sup>, Yun Zhu <sup>4</sup>, Hao Liu <sup>5</sup>, Shuanglan Xu <sup>6</sup>, Jie

6 Liu <sup>6</sup>, Jianping Liu <sup>7</sup>, Zhaowei Teng <sup>1\*</sup>, Xiguang Zhang <sup>1\*</sup>

7

8 <sup>1</sup> Department of Orthopedic Surgery, The People's Hospital of Yuxi City, The 6th

9 Affiliated Hospital of Kunming Medical University, Yuxi, Yunan, China

10 <sup>2</sup> Department of Pharmacy, The People's Hospital of Yuxi City, The 6th Affiliated

11 Hospital of Kunming Medical University, Yuxi, Yunan, China

12 <sup>3</sup> Department of General Medicine, The People's Hospital of Yuxi City, The 6th

13 Affiliated Hospital of Kunming Medical University, Yuxi, Yunan, China

14 <sup>4</sup> Department of Nephrology, The People's Hospital of Yuxi City, The 6th Affiliated

15 Hospital of Kunming Medical University, Yuxi, Yunan, China

16 <sup>5</sup> Department of Emergency Medicine, The People's Hospital of Yuxi City, The 6th

17 Affiliated Hospital of Kunming Medical University, Yuxi, Yunan, China

18 <sup>6</sup> Department of Respiratory Medicine, The Fourth Affiliated Hospital of Kunming

19 Medical University, The Second People's Hospital of Yunnan Province, Kunming,

20 China

<sup>7</sup> Department of Science and Education, The People's Hospital of Yuxi City, The 6th  
Affiliated Hospital of Kunming Medical University, Yuxi, Yunan, China

\* Corresponding authors

E-mail: tengzhaowei2003@163.com (TZW)

E-mail: gwkzxcg@163.com (ZXG)

## **Abstract**

### **Objective**

To assess the relationship between opioid therapy for chronic noncancer pain  
and fracture risk by a meta-analysis of cohort studies and case-control studies.

### **Methods**

The included cohort studies and case-control studies were identified by  
searching the PubMed and EMBASE databases from their inception until May 24,  
2019. The outcome of interest was a fracture. This information was independently  
screened by two authors. When the heterogeneity among studies was significant, a  
random effects model was used to determine the overall combined risk estimate.

### **Results**

In total, 12 cohort studies and 6 case-control studies were included. We used  
the Newcastle-Ottawa Scale (NOS) to evaluate the quality of the included literature,  
and 14 of the studies were considered high-quality studies. The overall relative risk of

opioid therapy and fractures was 1.78 (95% confidence interval (CI) 1.53 - 2.07). Subgroup analyses revealed sources of heterogeneity, sensitivity analysis was stable, and no publication bias was observed.

## Conclusions

The meta-analysis showed that the use of opioids significantly increased the risk of fracture.

## Introduction

With the advancement of society, the number of elderly people has gradually increased. Pain is a common symptom in the elderly population, and the incidence of chronic pain ranges from 25% to 76% [1]. Opioids provide effective analgesic effects in a range of persistent noncancer pain conditions and are widely used for the treatment of noncancer pain due to their analgesic and psychoactive effects [2]. There are many side effects of using opioids, such as dizziness, hypogonadism, and inhibition of the innate and acquired immune system. These side effects can lead to fractures. Vestergaard et al. [3] revealed that opioid-induced fractures may be associated with vertigo in patients after opioid use. Grey et al. [4] also confirmed that opioids cause fractures and that opioids act on the gonads to reduce bone density [4].

In addition, studies have shown that opioid-induced fractures are associated with time of use [5] and are also associated with the use of opioids [6]. Opioids have been linked to the occurrence of fractures [2,3,7-11], and although the use of opioids

has been reported to increase the risk of fractures, the trend of using opioids continues to increase [12]. However, in the previous studies, due to the influence of sample size, types of research, etc., there may have been inconsistencies, and we aimed to reconfirm the correlation between opioids and fracture risk while incorporating subsequently published studies.

## **Materials and methods**

### **Search strategy and data sources**

A search was conducted from the inception of the PubMed and EMBASE databases until May 20, 2019, to find relevant research that met the requirements. We also searched the bibliographies of relevant articles to identify additional studies. We used the following search terms: (i) fracture ? [Title/Abstract] OR “Fractures, Bone” [Mesh]; (ii) opioid ? [Title/Abstract] OR “Analgesics, Opioid” [Mesh].

### **Study selection**

Studies were considered eligible if they met all of the following criteria: (i) presented original data from the study; (ii) evaluated the association of opioid use with fracture incidence; (iii) had opioids as the exposure of interest; and (iv) provided hazard ratios and odd ratios (HRs and ORs) or the adjusted relative risks (RRs) and the corresponding 95% confidence intervals (CIs). If the data were duplicated or the

population was studied in more than one study, we included the study with the largest sample size and the most comprehensive outcome evaluation.

## Data extraction

Two investigators (YQN, ZXG) independently evaluated the eligibility of the studies retrieved from the databases based on the predetermined selection criteria. In addition, a cross-reference search of eligible articles was conducted to identify studies not found in the computerized search. These two authors independently extracted the following data: the first author's name; year of publication, patient ages, sample size, study regions, years of follow-up, study design, HR, OR or RR and the 95% CIs, and statistical adjustments for confounding factors. Any disagreements were resolved either by discussion or in consultation with the co-corresponding author (TZW). The Newcastle-Ottawa Scale (NOS) was used to evaluate the quality of the research [13].

## Statistical analyses

Our primary objective was to evaluate the use of opioids and the increased risk of fractures. We calculated total RR and 95% CI from the adjusted RRs, ORs or HRs and 95% CIs reported in the studies. ORs and HRs were considered to correspond to RRs. Using the Cochran Q and  $I^2$  statistic to assess statistical heterogeneity [14], we also calculated the P value of the q test representing heterogeneity; if the P value was

less than 0.10, there was heterogeneity among the studies. The fixed effects model was applied when  $I^2 < 50\%$  [15], otherwise, the random effects model was applied [16]; to further explore the source of heterogeneity, we also examined the study design, the study area and subfamily analysis of fracture types (i.e., any fracture, nonspine fracture, hip fracture). Additionally, Begg's rank correlation test and Egger's linear regression test were conducted to assess the extent of potential bias [17]. Finally, we conducted a sensitivity analysis to assess the stability of the analytical results by excluding each study to explore the impact of individual studies on the overall outcome [18]. The data analyses were conducted using STATA statistical software version 12.0 (STATA Corp. LLC, College Station, TX, USA).

## Results

### Literature search and study characteristics

Using predefined search strategies and inclusion criteria, a total of 18 studies were included and 1,134 articles of unrelated literature were excluded (from a total of 600 articles from PubMed and 552 articles from EMBASE) after a detailed reading of the title, abstract, and full text, and the 18 articles included 884054 participants [3,7,9,19-32]. The detailed process of inclusion in this study is shown in Fig 1. Five studies were from the United States [12,21,23,24,26,32], three from Canada [9,19,28], two from the United Kingdom [18,27], one study was from Australia, and the

125 remaining came from European countries; 12 articles were from cohort studies, and  
126 six were from case-control studies. The study information is shown in Table 1.

127 **Fig 1. Inclusion of Literature Search Flow Chart.**

128

129 **Table 1. Basic Characteristics of the 18 Included Studies.**

Author , year, location	Age, year s	Fracture type /assessment	Study design	Sample size	Follow-up time	Models	Adjustment for covariates	N
Jensen, 1991 , Denmark	>59	hip/WH O code 820	Case- control	400	from April to December 1988	Cornfield's iterative method	Age, sex, nursing home residency and number of hospital admissions	6
Shorr, 1992 , Canada	≥ 65	hip/ ICD-8, ICD-9	Case- control	2854 1	from 1997 to 1985	Unconditional logistic regression	Age, sex, home, hospital discharge in preceding year, index year	7
Guo, 1998 , Sweden	≥ 75	hip/IC D-9	Prospective cohort	1608	4.4 years	Cox proportional hazards	Age, sex, education, residence, ADL limitation, cognitive impairment, history of stroke and tumors	8

Ensrud, 2003, USA	$\geq 65$	fractures/radiology reports	Prospective cohort	8127	4.8 years	Cox proportional hazards	Age, sex, race, health status, smoking, walking exercise, functional impairment, cognitive function, depression, weight change	9
Card, 2004, UK	NA	hip/NA	Prospective cohort	99467	7.3 per 10000 person-years	Cox regression	Age, sex, practice, corticosteroid use	6
Sachin, 2006, USA	$\geq 65$	hip/ICD-9	Prospective cohort	362503	464 days	Cox regression	Age, sex, use of antidepressants, antipsychotics, anxiolytics/hypnotics	7
Vestergaard, 2006, Denmark	43.44 $\pm$ 27.39	hip/NA	Case-control	42065	during 2006	Conditional logistic regression	Use of other drugs	6
Kathleen, 2010, USA	$\geq 60$	fractures/ICD-9	Prospective cohort	2341	32.7 months	Cox proportional hazards	Age, gender, smoking, depression, substance abuse, dementia, comorbidity, prior fracture, pain site, antidepressant use, sedative use, HRT/bisphosphonate use	9
Miller, 2011, USA	$\geq 65$	fractures/ICD-9	Retropective cohort	17310	451 per 1000 person-years	Cox proportional hazards	Age, sex, diabetes, stroke, osteoarthritis, comorbidity index,	6



			t			ds	stroke, diabetes	
Vestergaard, 2012, Denmark	45 to 58	fractures /X-ray	Prospective cohort	2016	10 years	Cox proportional hazards	Age, HT, BMI, baseline spine bone mineral density (BMD), family or prior fracture, serum 25-hydroxy-vitamin levels and smoking	9
Laura, 2013, USA	$\geq 58.73 \pm 13.43$	lower extremity /ICD-9	Retropective cohort	7447	3-8 years	Cox proportional hazards	Age, race, completeness of spinal cord injury (SCI) level and duration of SCI	7
Lin Li, 2013, UK	18 to 80	fracture/NA	Nested case-control	71538	from 1990 to 2008	Conditional logistic regression	Smoking, BMI, comorbidities. Number of general practice visits recorded during the years before index date	7
Kristine, 2014, Sweden	$\geq 75$	hip/condyles S72.0, S72.1, S72.2	Retropective cohort	38407	during 2006	Multivariate logistic regression	Age, gender and morbidity level	8
Leach, 2015, Australia	>65	hip/ICD codes S72.0 or S72.1	Case-cross over	8828	from 2009 to 2012	Conditional logistic regression	NA	8

Acurcio, 2016, Canada	76.33 ± 10.04	fracture/ICD-9, ICD-10	Retropective nested case-control	9769	from 2007 to 2012	Conditional logistic regression	Age, sex, measures of comorbidities, history of arthroplasty, corticosteroid use, biologic agents or traditional disease-modifying antirheumatic drugs (DMARDs), use of other drugs potentially influencing the risk of fractures or falls, measures of health care resource use	7
Grewal, 2018, Canada	≥ 65	fracture/ICD-10	Retropective cohort	8989	3 months	Cox regression	Age, sex, past medical history, health care use, etc.	7
Taipale, 2018, Finland and	NA	hip fracture/ICD-10	Retropective matched cohort	7071	5 years	Cox proportional hazard	Age, sex, time since Alzheimer's disease (AD) diagnosis, socioeconomic position, university hospital catchment area, use of drugs, comorbidities	9
Vakharia, 2019, USA	≥ 64	fracture/ICD-9 (81.54) codes 304.00-304.02 and 305.50-305.52.	Retropective matched cohort	2307	from 2005 to 2014	R Statistical analysis	Age, sex, use of drugs	7

130

## 131 **Main analysis**

132       There was a positive correlation between the use of opioids and fractures (RR  
133 1.78, 95% CI 1.53-2.07) (Fig 2), and we observed significant heterogeneity among the  
134 studies. Eleven studies provided data on opioid use and hip fracture risk  
135 [3,7,19-23,27,29-31]. Pooled studies showed that the use of opioids had a significant  
136 impact on the risk of hip fracture (RR 1.56, 95% CI 1.37-1.79), and there was  
137 significant heterogeneity among the studies ( $P = 0.000$ ,  $I^2 = 83.1\%$ ) (Fig 3); we  
138 subsequently revealed the sources of heterogeneity through subgroup analyses.

139 **Fig 2. Forest Plot of RR with 95% CI for Opioid Use and Fracture Risk.**

140 **Fig 3. Forest Plot of RR with 95% CI for Opioid Use and Hip Fracture Risk.**

141

## 142 **Subgroup meta-analysis**

143       We performed a subgroup analysis based on the type of study, region, and  
144 fracture type, and the risk of fractures was positively correlated with the use of  
145 opioids (Table 2). Subgroup analyses showed a significant increase in fracture risk  
146 after opioid use, with no statistical heterogeneity among studies conducted in the  
147 European region, Britain, and Denmark (Fig 4). Although Shorr et al. [19] was a  
148 case-control study, the control data were derived from the hospital database, which  
149 make it a retrospective study together with the studies of Miller, Laura, Grewal,  
150 Kristine and Vakharia et al. [9,24,26,29,32]. To determine the impact of these

retrospective studies, we conducted further analyses without the above studies, and the overall results showed that heterogeneity significantly decreased.

#### **Fig 4. Forest Plot for a Subgroup Meta-Analysis by Region.**

**Table 2. Subgroup Analyses of the Association between Opioid Use and Fracture Risk.**

	Factor	No. of studies	RR (95% CI)	Heterogeneity P (I <sup>2</sup> )
Study design	Case-control	6	1.57 (1.23, 2.02)	0.000 (95.6)
	Prospective cohort	6	1.62 (1.31, 2.02)	0.003 (72.5)
	Retrospective cohort	6	2.32 (1.69, 3.19)	0.000 (93.0)
Fracture type	Hip fracture	9	1.62 (1.41, 1.87)	0.000 (81.3)
	Nonspine fracture	2	2.03 (1.00, 4.13)	0.000 (95.1)
	Any fracture	7	1.97 (1.43, 2.69)	0.000 (93.5)

#### **Sensitivity analysis**

To assess the stability of our results, based on the original data, sensitivity analyses were performed using a strategy that systematically excluded individual studies. In the end, there was no change in the overall results (Fig 5).

**Fig 5. Sensitivity Analysis of the Association between Opioid Use and Fracture Risk.**

#### **Publication bias**

No evidence of publication bias was found based with Begg's rank correlation test ( $p > |z| = 0.649$ ) or Egger's linear regression test ( $p > |z| = 0.067$ ) (Figs 6 and 7).

**Fig 6. Begg's Funnel Plot.**

**Fig 7. Egger's Publication Bias Plot.**

## **Discussion**

The trend of population aging is becoming more pronounced, and most of the fracture patients are elderly individuals. The elderly population has a higher fracture rate due to lower bone density. Elderly individuals are more likely to be in poor physical condition, most of them have a history of chronic pain resulting in a history of taking opioids, and the probability of fractures increases. Therefore, the incidence of fractures caused by opioids is discussed below. There is a high potential for associations between opioids and fractures.

In this meta-analysis, we included the latest basic research. The types of studies included in this analysis included case-control studies, the sample size was increased, and the study area was refined. The results showed that the use of opioids increased the risk of fracture. Previously, the most recent meta-analysis (Ping et al. [33]) was limited to the study of hip fractures, and Grewal et al. [9] showed that patients taking opioids had a risk of fracture after discharge compared with patients who were not taking opioids. The main reason for the increase was that patients taking opioids were prone to vertigo and falls that can lead to fractures. In addition, Aspinall's et al. [6] study showed that patients receiving opioid therapy had an increased risk of falls, and the accompanying final outcomes were fractures [6].

Schwarzer et al's [8] study also suggested that when opioid use was considered, the risk of fractures increased [8]. The above studies are consistent with our final results and support our findings. In addition, there are two main mechanisms for the occurrence of fractures with opioid use. One mechanism is that opioids may reduce bone density by inhibiting the production of endogenous sex hormones, leading to an increased risk of fractures [34]; the other mechanism involves the side effects of opioids, such as the central nervous system side effects of vertigo, fatigue, etc., that lead to the occurrence of fractures [7,9,27,28], and there is a high incidence of side effects, including acute cognitive deterioration, increased sputum production, decreased oxygen saturation, and constipation, after the use of opioids in elderly populations, as confirmed in recent studies [35]. The trend of the population aging is becoming increasingly pronounced, and osteoporosis in this aging population is a serious concern. The use of opioids in this population leads to more frequent fractures.

The relationships among opioids, analgesia and fracture have been examined, and we have previously published relevant articles [36]. However, for the present analysis, we included cohort studies and case-control studies, in which patients were followed up over a long time. Most of the research was of high quality, the sample sizes were large enough, and the outcome evaluations were reliable and comprehensive. In addition, although our overall analysis showed heterogeneity, we determined the source of the heterogeneity through subgroup analyses. For example,

Shorr, Grewal, Miller, and Laura were all retrospective studies [9,19,24,26]. In the subgroup analysis, heterogeneity was significantly reduced suggesting that these retrospective cohort studies may have been a source of heterogeneity. Based on a regional subgroup analysis, we found that the research conducted in Canada and the United States made an important contribution to the heterogeneity (Fig 5). Therefore, we believe that geography is one of the important reasons for the heterogeneity. Next, we individually examined the heterogeneity in the Canadian group of studies. When we excluded the study by Shorr et al. [19], we found that there was no heterogeneity among the Canadian group of studies ( $I^2=0.0\%$ ,  $p=0.470$ ) and in the hip fracture group of studies. Regarding the larger source of heterogeneity, we finally found the source through analysis and mainly identified the role of retrospective cohort studies and case-control studies. This comprehensive analysis suggested that heterogeneity mainly comes from retrospective articles and may also be caused by other factors, such as geographical factors, and we will continue to pay attention to these factors in the future.

Although our research has many advantages, it also has shortcomings. First, due to language limitations, the included studies were limited to English, and these language limitations may have led to studies not being included, resulting in a dataset that was not quite comprehensive. Second, some studies that are not statistically significant or have negative findings may not have been published because they were rejected by the journal or because the researcher was unwilling to submit such a

publication. We also performed a publication bias test, but it is also possible that the effect value was overestimated when studies with a large degree of heterogeneity were combined. Again, the degree of control over confounding variables, such as age and gender, varied from study to study. In our meta-analysis, the timing and dose of the drug could not be studied because the time frames were different across studies. Thus, we were unable to unify the timing, and the drug dose was also different based on varying classification criteria and could not be further studied. Finally, the study participants were all Westerners, and the influencing factors were complex and variable. Therefore, we should pay attention to the global situation in these populations to improve and validate the conclusions. It was also impossible to conduct further analyses as to whether the length of metabolism for a particular drug was an influencing factor, and this issue is worthy of attention in the future. We have included a number of different studies covering a wide range clinical and experimental factors and the results were still stable, and we will conduct a more comprehensive analysis when future conditions permit.

## Conclusions

Taken together, we included different types of studies, and the results still indicated that the use of opioids significantly increased the risk of fracture. Further research, including well-designed international trials, studies of the mechanisms by



which opioid use causes fractures, and studies aimed at preventing such fractures require more evidence from clinical practice.

## Acknowledgments

We appreciate the contribution of all patients, their families, the investigators and the medical staff.

## References

1. Abdulla A, Adams N, Bone M, Elliott AM, Gaffin J, Jones D, et al. Guidance on the management of pain in older people. *Age Ageing*. 2013;42 Suppl 1: i1-i57.
2. Stewart G, Owen M. Opioids in the management of persistent non-cancer pain. *Anaesth Intensive Care*. 2013;14: 533-535.
3. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with the use of morphine and opiates. *J Intern Med*. 2006;260: 76-87.
4. Grey A, Rix-Trott K, Horne A, Gamble G, Bolland M, Reid IR. Decreased bone density in men on methadone maintenance therapy. *Addiction*. 2011;106: 349-354.
5. Lindestrand AG, Christiansen ML, Jantzen C, van der Mark S, Andersen SE. Opioids in hip fracture patients: an analysis of mortality and post hospital opioid use. *Injury*. 2015;46: 1341-1345.

- 272 6. Aspinall SL, Springer SP, Zhao X, Cunningham FE, Thorpe CT, Semla TP, et  
273 al. Central nervous system medication burden and risk of recurrent serious  
274 falls and hip fractures in veterans affairs nursing home residents. *J Am Geriatr*  
275 *Soc.* 2019;67: 74-80.
- 276 7. Taipale H, Hamina A, Karttunen N, Koponen M, Tanskanen A, Tiihonen J, et  
277 al. Incident opioid use and risk of hip fracture among persons with Alzheimer  
278 disease: a nationwide matched cohort study. *Pain.* 2019;160: 417-423.
- 279 8. Schwarzer A, Kaisler M, Kipping K, Seybold D, Rausch V, Maier C, et al.  
280 Opioid intake prior to admission is not increased in elderly patients with  
281 low-energy fractures: a case-control study in a German hospital population.  
282 *Eur J Pain.* 2018;22: 1651-1661.
- 283 9. Grewal K, Austin PC, Kapral MK, Lu H, Atzema CL. The impact of opioid  
284 medications on subsequent fractures in discharged emergency department  
285 patients with peripheral vertigo. *CJEM.* 2018;20: 28-35.
- 286 10. Hirst A, Knight C, Hirst M, Dunlop W, Akehurst R. Tramadol and the risk of  
287 fracture in an elderly female population: a cost utility assessment with  
288 comparison to transdermal buprenorphine. *Eur J Health Econ.* 2016;17:  
289 217-227.
- 290 11. Spector W, Shaffer T, Potter DE, Correa-de-Araujo R, Rhona Limcangco M.  
291 Risk factors associated with the occurrence of fractures in U.S. nursing homes:

292 resident and facility characteristics and prescription medications. J Am Geriatr  
293 Soc. 2007;55: 327-333.

294 12. Saunders KW, Dunn KM, Merrill JO, Sullivan M, Weisner C, Braden JB, et  
295 al. Relationship of opioid use and dosage levels to fractures in older chronic  
296 pain patients. J Gen Intern Med. 2010;25: 310-315.

297 13. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The  
298 Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised  
299 studies in meta-analyses. Ottawa, ON: Ottawa Hospital Research Institute;  
300 2013.

301 14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in  
302 meta-analyses. BMJ. 2003;327: 557-560.

303 15. Leonard T, Duffy JC. A Bayesian fixed effects analysis of the  
304 Mantel-Haenszel model applied to meta-analysis. Stat Med. 2002;21:  
305 2295-2312.

306 16. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat  
307 Med. 2002;21: 1539-1558.

308 17. Harbord RM, Egger M, Sterne JA. A modified test for small-study effects in  
309 meta-analyses of controlled trials with binary endpoints. Stat Med. 2006;25:  
310 3443-3457.

311 18. Chootrakool H, Shi JQ, Yue R. Meta-analysis and sensitivity analysis for  
312 multi-arm trials with selection bias. Stat Med. 2011;30: 1183-1198.

- 313 19. Shorr RI, Griffin MR, Daugherty JR, Ray WA. Opioid analgesics and the risk  
314 of hip fracture in the elderly: codeine and propoxyphene. *J Gerontol.* 1992;47:  
315 M111-M115.
- 316 20. Guo Z, Wills P, Viitanen M, Fastbom J, Winblad B. Cognitive impairment,  
317 drug use, and the risk of hip fracture in persons over 75 years old: a  
318 community-based prospective study. *Am J Epidemiol.* 1998;148: 887-892.
- 319 21. Ensrud KE, Blackwell T, Mangione CM, Bowman PJ, Bauer DC, Schwartz A,  
320 et al. Central nervous system active medications and risk for fractures in older  
321 women. *Arch Intern Med.* 2003;163: 949-957.
- 322 22. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with  
323 inflammatory bowel disease and their relationship to corticosteroid use: a  
324 population based cohort study. *Gut.* 2004;53: 251-255.
- 325 23. Kamal-Bahl SJ, Stuart BC, Beers MH. Propoxyphene use and risk for hip  
326 fractures in older adults. *Am J Geriatr Pharmacother.* 2006;4: 219-226.
- 327 24. Miller M, Sturmer T, Azrael D, Levin R, Solomon DH. Opioid analgesics and  
328 the risk of fractures in older adults with arthritis. *Journal of the American*  
329 *Geriatrics Society.* 2011;59: 430-438.
- 330 25. Vestergaard P, Hermann P, Jensen JE, Eiken P, Mosekilde L. Effects of  
331 paracetamol, non-steroidal anti-inflammatory drugs, acetylsalicylic acid, and  
332 opioids on bone mineral density and risk of fracture: results of the Danish  
333 Osteoporosis Prevention Study (DOPS). *Osteoporos Int.* 2012;23: 1255-1265.

334 26. Carbone LD, Chin AS, Lee TA, Burns SP, Svircev JN, Hoenig HM, et al. The  
335 association of opioid use with incident lower extremity fractures in spinal cord  
336 injury. *J Spinal Cord Med.* 2013;36: 91-96.

337 27. Li L, Setoguchi S, Cabral H, Jick S. Opioid use for noncancer pain and risk of  
338 fracture in adults: a nested case-control study using the general practice  
339 research database. *Am J Epidemiol.* 2013;178: 559-569.

340 28. Acurcio FA, Moura CS, Bernatsky S, Bessette L, Rahme E. Opioid use and  
341 risk of nonvertebral fractures in adults with rheumatoid arthritis: a nested  
342 case-control study using administrative databases. *Arthritis Rheumatol.*  
343 2016;68: 83-91.

344 29. Thorell K, Ranstad K, Midlov P, Borgquist L, Halling A. Is use of fall  
345 risk-increasing drugs in an elderly population associated with an increased risk  
346 of hip fracture, after adjustment for multimorbidity level: a cohort study. *BMC*  
347 *Geriatr.* 2014;14: 131.

348 30. Leach MJ, Pratt NL, Roughead EE. Psychoactive medicine use and the risk of  
349 hip fracture in older people: a case-crossover study. *Pharmacoepidemiol drug*  
350 *saf.* 2015;24: 576-582.

351 31. Jensen J, Nielsen LH, Lyhne N, Hallas J, Brosen K, Gram LF. Drugs and  
352 femoral neck fracture: a case-control study. *J Intern Med.* 1991;229: 29-33.

353 32. Vakharia RM, Sabeh KG, Vakharia AM, Damodar DM, Law TY, Roche MW.  
354 Comparison of implant related complications amongst patients with opioid use

- 355 disorder and non-users following total knee arthroplasty. World J Orthop.
- 356 2019;10: 137-144.
- 357 33. Ping F, Wang Y, Wang J, Chen J, Zhang W, Zhi H, et al. Opioids increase hip
- 358 fracture risk: a meta-analysis. J Bone Miner Metab. 2017;35: 289-297.
- 359 34. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The
- 360 comparative safety of analgesics in older adults with arthritis. Arch Intern
- 361 Med. 2010;170: 1968-1976.
- 362 35. Dagenais-Beaule V, Tourigny JF, Papillon-Ferland L. Opioid use and pain
- 363 control in the elderly after elective or urgent orthopaedic surgery: a
- 364 retrospective cohort study. Clin Drug Investig. 2019;39: 301-308.
- 365 36. Teng Z, Zhu Y, Wu F, Zhu Y, Zhang X, Zhang C, et al. Opioids contribute to
- 366 fracture risk: a meta-analysis of 8 cohort studies. PLoS One. 2015;10:
- 367 e0128232.
- 368

## 369 **Supporting information**

370 **S1 Table. PRISMA 2009 checklist**

371 (DOC)

372 **S2 EDITORIAL CERTIFICATE**

373 (PDF)




Fig1




Fig2






Fig3




Fig4

# Meta-analysis random-effects estimates (exponential form)

Study omitted




Fig5

Begg's funnel plot with pseudo 95% confidence limits




Fig6

Egger's publication bias plot




Fig7